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Abstract 23 
Aims/hypothesis: Recent studies suggest that a circulating protein called TRAIL (TNF-related 24 
apoptosis-inducing ligand) may have an important role in the treatment of type 2 diabetes. It has been 25 
shown that TRAIL deficiency worsens diabetes and that TRAIL delivery, when it is given before 26 
disease onset, slows down its development. This study aimed at evaluating whether TRAIL had the 27 
potential not only to prevent, but also to treat type 2 diabetes. 28 
Methods: Thirty male C57BL/6J mice were randomized to a standard or a high-fat diet (HFD). After 4 29 
weeks of HFD, mice were further randomized to receive either placebo or TRAIL, which was delivered 30 
weekly for 8 weeks. Body weight, food intake, fasting glucose and insulin were measured at baseline 31 
and every 4 weeks. Tolerance tests were performed before drug randomization and at the end of the 32 
study. Tissues were collected for further analyses. Parallel in vitro studies were conducted on HepG2 33 
cells and mouse primary hepatocytes.    34 
Results: TRAIL significantly reduced body weight, adipocyte hypertrophy, free fatty acid levels and 35 
inflammation. Moreover, it significantly improved impaired glucose tolerance, and ameliorated non-36 
alcoholic fatty liver disease (NAFLD). TRAIL treatment reduced liver fat content by 47% in vivo as 37 
well as by 45% in HepG2 cells and by 39% in primary hepatocytes. This was associated with a 38 
significant increase of liver PGC-1α expression both in vivo and in vitro, pointing to a direct protective 39 
effect of TRAIL on the liver.    40 
Conclusion/interpretation: This study confirms the ability of TRAIL to attenuate significantly diet-41 
induced metabolic abnormalities, and it shows for the first time that TRAIL is effective also when 42 
administered after disease onset. In addition, our data sheds light on TRAIL therapeutic potential not 43 
only against impaired glucose tolerance, but also against NAFLD. 44 
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Abbreviation list 47 
AOX, Acyl-CoA oxidase; ATG7, autophagy-related protein 7; CPT carnitine palmitoyl transferase; 48 
CPT1a, carnitine palmitoyl transferase-1a; CRP, C-reactive protein; CYT SYNT, cytrate synthase; FAS 49 
fatty acid synthase; gp91phox is a subunit of NADPH oxidase; HFD, high-fat diet; IPITT, 50 
intraperitoneal insulin tolerance test; HNF4, hepatocyte nuclear factor 4; MCP1, monocyte 51 
chemoattractant protein-1; NAFLD, non-alcoholic fatty liver disease; NASH, non-alcoholic 52 
steatohepatitis; PGC-1α, peroxisome proliferator-activated receptor-γ coactivator-1 alpha; pgWAT, 53 
perigonadal white adipose tissue; PLN5, perilipin 5; PPARα, peroxisome proliferator-activated 54 
receptor-α; PPARγ, peroxisome proliferator-activated receptor-γ.; SIRT1, sirtuin-1; SREBP1a,  sterol 55 
regulatory element binding protein-1a; SREBP1c, sterol regulatory element binding protein-1c; 56 
TRAIL, TNF-related apoptosis-inducing ligand; UCP2, uncoupling protein.  57 
  58 
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Introduction 59 
TRAIL is an acronym for TNF-related apoptosis-inducing ligand, which is a circulating protein 60 
belonging to the TNF superfamily. Like other members of this family, such as FasL and TNFα, TRAIL 61 
has the ability to induce programmed cell death (apoptosis). However, as compared to them, TRAIL 62 
hits preferentially transformed cells, such as cancer cells, while sparing the normal ones (1). In non-63 
malignant cells, TRAIL actions remain largely unexplored.  64 
Recent experimental evidence suggests that TRAIL has significant metabolic effects (2, 3), and might 65 
be involved in the regulation of obesity and diabetes mellitus, as well as their complications. The first 66 
studies reporting TRAIL beneficial effects on diabetes were carried out in models of type 1 diabetes 67 
and showed that TRAIL attenuated disease development and progression (4, 5) with partial 68 
preservation of islet morphology (6). More recently, we reported that TRAIL delivery significantly 69 
reduced the metabolic abnormalities of an experimental model of type 2 diabetes (7). Consistent with 70 
these observations, other groups have shown that genetic lack of TRAIL worsened both forms of 71 
diabetes and their associated diseases (8), such as atherosclerosis (8) and non-alcoholic fatty liver 72 
disease (NAFLD) (9).  73 
The high-fat diet (HFD)-fed mouse is one of the models suitable for the study of type 2 diabetes (10). 74 
After a few weeks, the HFD usually increases body weight and fat mass, leading to peripheral insulin 75 
resistance and impaired glucose tolerance, with subsequent hyperglycemia and hyperinsulinemia (10). 76 
Although the HFD-fed mouse does not always develops diabetes, but rather impaired glucose 77 
tolerance, it has the advantage of reproducing the human situation more accurately than genetic models 78 
of obesity-induced diabetes (11). Moreover, it allows for the study of common and burdensome 79 
diabetic comorbidities, such as obesity, NAFLD, and non-alcoholic steatohepatitis (NASH) (12). 80 
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A few years ago, we reported that TRAIL significantly ameliorated the metabolic abnormalities of the 81 
HFD-fed mouse. In that paper, TRAIL treatment was started before the development of metabolic 82 
abnormalities, following a preventive treatment schedule. In this study, we aimed at evaluating the 83 
therapeutic potential of TRAIL against type 2 diabetes. For this reason, TRAIL treatment was started 84 
after the development of metabolic abnormalities, following a therapeutic schedule. Here we report the 85 
effects of TRAIL treatment on glucose tolerance and on the tissues regulating it. 86 
 87 
  88 
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Materials and Methods 89 
Recombinant human TRAIL (rhTRAIL) 90 
Recombinant histidine 6-tagged human TRAIL (114-281) was produced in transforming bacteria BL21 91 
with a pTrc-His6 TRAIL vector, as described (13) and detailed in the Supplementary Material and 92 
Methods. 93 
Experimental protocol 94 
As reported in Figure 1A, thirty 8-week-old C57BL/6J male mice (Harlan Laboratories, Udine, Italy) 95 
were randomized to receive either a standard diet (CNT, n=10) or a high-fat diet (HFD, n=20) for 12 96 
weeks. After 4 weeks from diet randomization, HFD mice were randomly allocated to receive either 97 
saline (HFD, n=10) or rhTRAIL (HFD + TRAIL, n=10) for the remaining 8 weeks. CNT mice received 98 
saline (NaCl 0.9%) as well. rhTRAIL (TRAIL) was given at a dose of 10 μg/200μL per mouse by 99 
weekly intraperitoneal (IP) injection. Standard diet provided 22% of calories from protein, 66% of 100 
calories from carbohydrate, and 12% of calories from fat, and a digestible energy of 3.0 Kcal/g 101 
(Tekland Global 16% Protein Rodent Diet, Harlan Laboratories). HFD provided 18.4% of calories from 102 
protein, 21.3% of calories from carbohydrate, and 60% of calories from fat, and a digestible energy of 103 
5.1 Kcal/g (TD 06.414 Adjusted calories diet 60/fat, Harlan Laboratories). Animals were kept (5/cage) 104 
in ventilated cabinets (Tecniplast Spa, Buggiate, Varese, Italy), in specific-pathogen-free and 105 
temperature-controlled rooms (22°C), with relative humidity of 50-70%, on a 12h light/12h dark cycle. 106 
They had free access to food and water, and they were fed ad libitum for the length of the study. During 107 
the 12-week study period, body weight, food intake, glucose, and insulin were measured at baseline 108 
and at 4-week intervals. Tolerance tests were performed before drug randomization and at the end of 109 
the study. At the end of the study, animals were anesthetized by an IP injection of tiletamine/zolazepam 110 
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(80mg/kg). Blood was collected from the left ventricle, centrifuged, and serum was stored for further 111 
analyses (total cholesterol, HDL cholesterol, triglycerides, free fatty acids, C-reactive protein). 112 
Pancreas, perigonadal white adipose tissue (pgWAT), liver, and quadriceps were weighed and either 113 
snap frozen or fixed in formalin for further analyses. 114 
The Guide for the Care and Use of Laboratory Animals, 8th edition (2011), as well as specific 115 
European (86/609/EEC) and Italian (D.L.116/92) laws were followed. In compliance with the principle 116 
of reducing as much as possible the number of mice studied, we did not include CNT mice + TRAIL 117 
because we have previously observed and reported that repeated injections of TRAIL (providing a 118 
cumulative dose of 100 μg/mouse) did not affect glucose, insulin, and/or body weight in normal 119 
conditions in vivo (6). This study was approved by the Institutional Animal Care and Use Committee of 120 
the Cluster in Biomedicine (CBM) and by the Italian Ministry of Health (DM 17/2001 A dd. 121 
02/02/2011). The study period was June 2015-May 2017. 122 
Assessment of TRAIL biodistribution 123 
In order to evaluate TRAIL bioavailability when delivered by IP injection, 20-week-old C57BL/6J 124 
male mice (n=3) received 10 μg of Cy5.5-TRAIL by IP injection, and fluorescence in the peritoneal 125 
cavity was acquired at baseline and after 30 minutes, 6 hours, and 30 hours post-injection, as 126 
previously reported (14). The details of TRAIL labeling are in the Supplementary Materials and 127 
Methods. In addition, 20-week-old C57BL/6J male mice (n=8) received 10 μg of TRAIL by IP 128 
injection, bloods were collected at baseline and after 6, 30, 48, and 72 hours, and TRAIL was measured 129 
by ELISA (R&D; #DTLR00).  130 
General parameters and biochemistries 131 
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Food intake was measured by placing in the cages pellets previously weighed in total. The food that 132 
was left over was collected and weighed to find the amount eaten. Energy intake was measured 133 
according to the digestible energy provided by both diets. Fasting glucose was measured by glucometer 134 
(Glucomen LX Plus, Menarini). Fasting insulin was measured by ELISA (Millipore; #EZRMI-13K). 135 
NEFA concentrations were measured by colorimetric assay (Sigma; #MAK044-1KT). Circulating total 136 
cholesterol, HDL cholesterol, and triglycerides were measured with the AU5800 analyzer (Beckman 137 
Coulter) by enzymatic colorimetric method, while C-reactive protein (CRP) was measured by 138 
immunoturbidimetric method.  139 
Tolerance tests 140 
The intraperitoneal glucose tolerance test (IPGTT) was performed on day 1 of week 4 and week 12 by 141 
injecting glucose (2 g/kg) intraperitoneally after an overnight fast. Glucose and insulin were measured 142 
at baseline and at 15, 60, and 120 min. The intraperitoneal insulin tolerance test (IPITT) was performed 143 
on day 1 of week 3 and week 11 by injecting insulin (1 unit/kg) intraperitoneally after a 6-hour fast. 144 
Glucose was measured at baseline, and at 30, 60, and 120 min.   145 
Tissue Stainings 146 
Adipocyte area was measured on pgWAT paraffin sections (4 μm) stained with H&E. pgWAT 147 
macrophages were detected by F4/80 immunostaining (1:100 dilution, applied overnight; Abcam 148 
#Ab111101) and reported as positive nuclei/100 nuclei. Pancreatic beta cell density and mass were 149 
estimated as previously described (15) on paraffin sections (4 μm) by insulin immunostaining (1:100 150 
applied overnight; DAKO #A0564). Liver steatosis was evaluated on frozen sections (5 μm) stained 151 
with Oil-Red-O, where fat was quantified as % of positive (red) staining/tissue area. The same method 152 
was used for skeletal muscle fat content. For liver fibrosis, paraffin sections (4 μm) were stained with 153 
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Picrosirius Red, and fibrosis was quantified as % of positive (red) staining/tissue area (15). Liver 154 
macrophages were detected on frozen sections (5 μm) by CD68 immunostaining (1:50 applied 155 
overnight; Serotec #MCA1957S), and they were reported as positive nuclei/frame. Liver PGC-1α 156 
expression was measured on paraffin sections (4 μm) by PGC-1α immunostaining (1:50 applied 157 
overnight; Abcam #ab191838) and was reported as the % of positive (brown) staining/tissue area. All 158 
the sections were examined by light microscopy (Carl Zeiss - Jenaval) and digitized using a high-159 
resolution camera (Q-Imaging Fast 1394). The % of staining/tissue area was quantified using Image-160 
ProPlus 6.3 (Media Cybernetics, Bethesda, MD, USA). Quantifications were performed on 40-100 161 
frames per group. 162 
Liver triglyceride content 163 
For liver triglycerides (TG), 100 mg of liver were homogenized in 1 ml of 5% NP40. Samples were 164 
heated at 95° for 5 minutes, cooled down at RT for 5 minutes twice, and then centrifuged to collect the 165 
supernatants. Triglycerides were measured with the AU5800 analyzer (Beckman Coulter) by enzymatic 166 
colorimetric method (for details, see the Supplementary Materials and Methods). 167 
Gene expression quantification by RT-qPCR 168 
Gene expression was determined by real-time quantitative RT-qPCR. In order to isolate mRNA, tissue 169 
was homogenized and processed as previously reported (16). Then, mRNA was treated to eliminate 170 
DNA contamination (Ambion DNA-free product #AM-1906), and 3 μg of treated mRNA were 171 
subsequently used to synthesize cDNA with Superscript First Strand synthesis system for RT-PCR 172 
(Gibco BRL). The gene expression of Fas, Srebp1a, Srebp1c, Acox, Cpt1a, Pparα, Irs2, Pepck, Pparγ, 173 
Hnf4, Citrate synthase, Pgc-1α, Ucp2, Sirt, Pln, Gp91phox, Il-6, Tnfα, and Atg7 was analyzed by RT-174 
qPCR using the SYBR Green system (Life Technologies). Mcp1 was analyzed using the Taqman 175 
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system (Life Technologies). Fluorescence for each cycle was quantitatively analyzed by StepOnePlus 176 
real-time PCR system (Applied Biosystems). Gene expression was normalized to Rps9 or 18s. Results 177 
are reported as ratio compared with the level of expression in untreated controls, which were given an 178 
arbitrary value of 1. Primers are reported in Supplementary Table 1.  179 
In vitro studies on HepG2 cells and mouse primary hepatocytes 180 
Human hepatocellular carcinoma cells (HepG2) obtained from ATCC were cultured in high glucose 181 
DMEM, supplemented with 10% (v/v) fetal bovine serum, L-glutamine (2mM), penicillin (100U/mL), 182 
and streptomycin (100 μg/mL) in a 5% CO2 atmosphere at 37°C. In order to mimic a high-fat diet 183 
milieu, cells were grown in media supplemented with either BSA-conjugated palmitate (250 mM) or 184 
BSA-conjugated oleate (250 mM). Cells were cultured for 24 hours with BSA-conjugated oleate with 185 
or without TRAIL (1 ng/mL) for cell viability, lipid accumulation, and protein expression studies, 186 
while they were cultured for 6 hours for gene expression analysis. Cell viability was assessed with the 187 
MTT assay (Alfa Aesar; #L11939). Total intracellular lipid content was evaluated by Oil-Red-O 188 
staining. Protein expression of PGC-1α was analyzed by immunofluorescence. Gene expression of 189 
PPARγ, PGC-1α, and ATG7 was analyzed by RT-qPCR using the SYBR Green system (Life 190 
Technologies). cDNA was synthesized as detailed for our in vivo analyses. Fluorescence for each cycle 191 
was quantitatively analyzed by StepOnePlus real-time PCR system (Applied Biosystems). Gene 192 
expression was normalized to GADPH or Rpl27, and reported as a ratio compared to the level of 193 
expression in untreated controls, which were given an arbitrary value of 1. Primers are reported in 194 
Supplementary Table 1.  195 
In addition, in parallel in vitro studies, mouse primary hepatocytes were isolated from C57BL/6J male 196 
mice following a protocol adapted from Severgnini (17). After digestion with collagenase IV, liver 197 
suspension was passed through a cell strainer. Primary hepatocytes were washed 4 times and seeded on 198 
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pre-coated plates with a plating medium (Williams E Medium supplemented with CM3000, 199 
ThermoFisher Scientific) for 5 hours in a 5% CO2 atmosphere at 37°C. Then, this medium was 200 
changed to a maintenance solution (CM4000 ThermoFisher Scientific) for 24 hours before starting the 201 
treatment. As before, primary hepatocytes were cultured for 24 hours with BSA-conjugated oleate 202 
(250mM) or BSA alone, with or without TRAIL (1 ng/mL). Total intracellular lipid content was 203 
evaluated by Oil-Red-O staining.  204 
 205 
Statistics 206 
Results are expressed as means ± standard error of the mean (SEM). Differences in the mean among 207 
groups were analyzed using one-way or two-way ANOVA. Pairwise multiple comparisons were made 208 
using Bonferroni post-hoc analysis. A threshold of p<0.05 was considered statistically significant. 209 
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Results 210 
Animal model and in vivo bioavailability of TRAIL 211 
Mice were put on a high-fat dietary regime to induce obesity and associated metabolic comorbidities 212 
(Figure 1A). After 4 weeks, before drug randomization, HFD mice had increased in weight (6.3 ± 0.6 213 
g) as compared to CNT mice (3.7 ± 0.6 g; p<0.05 vs HFD). HFD mice weighed 30.4 ± 0.5 g and CNT 214 
mice weighed 28.9 ± 0.7 g. There were no differences between the groups in terms of fasting glucose 215 
and insulin. Nevertheless, the glucose and insulin tolerance tests showed that HFD mice had developed 216 
impaired glucose tolerance as compared to CNT mice (Figure 1B). At this stage, HFD mice were 217 
randomized to receive either TRAIL or saline by weekly IP injection for 8 weeks. This schedule was 218 
chosen based on our previous study (7). Mice tolerated this treatment well, and they did not show any 219 
sign of distress during the study or gross abnormalities at necroscopic examination as compared to 220 
those treated with saline, in line with previous reports (18). When we then looked at TRAIL 221 
bioavailability, we found that TRAIL was detectable after 6 hours from the IP injection and then 222 
disappeared 24 hours later. This data was in line with our imaging experiment showing that the highest 223 
fluorescence signal of Cy5.5-TRAIL was detected 6 hours after the IP injection, and then tended to 224 
decrease over time (Figure 1C-D).  225 
TRAIL treatment significantly reduced obesity, as well as adipose and systemic inflammation 226 
At the end of the study, HFD mice became obese as compared to CNT mice. TRAIL treatment 227 
significantly reduced body weight gain in HFD mice (Figure 2A), without affecting their food and 228 
energy intake. In particular, HFD mice ate 2.7 ± 0.2 g/day with an energy intake of 13.7 ± 1.2 229 
Kcal/day, as compared to HFD+TRAIL mice, who ate 2.6 ± 0.3 g/day with an energy intake of 13.4 ± 230 
1.3 Kcal/day. Secondly, HFD mice exhibited WAT hypertrophy, as assessed by pgWAT weight 231 
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(Figure 2B), which is considered one of the largest visceral WAT depots (19). This was associated 232 
with an increase in the adipocyte area (Figure 2C-E) and the number of infiltrating macrophages 233 
(Figure 2E-F). TRAIL treatment significantly reduced WAT hypertrophy, adipocyte area, and 234 
macrophage accumulation in the WAT (Figure 2B-F). Thirdly, HFD mice exhibited higher levels of 235 
NEFA and CRP  (Figure 2G-I), in line with the concept that excess fat is associated with high levels of 236 
NEFA (20) and a low-grade systemic inflammatory state (21). TRAIL treatment significantly reduced 237 
both NEFA and CRP (Figure 2G-I). Interestingly, TRAIL treatment was associated with a significant 238 
increase in total cholesterol, driven by an increase in HDL cholesterol.  239 
TRAIL treatment significantly reduced impaired glucose tolerance. 240 
The tolerance tests (Figure 3A-F) performed at the end of the study showed that the HFD resulted in 241 
impairment of glucose clearance, leading to significant hyperglycemia and hyperinsulinemia 2 hours 242 
after a glucose load (Figure 3D-E). This was associated with the inability of insulin to lower glucose 243 
levels to the levels of CNT mice (Figure 3F). At fasting, glucose did not differ between the groups, 244 
and HFD mice displayed only a significant hyperinsulinemia as compared to CNT mice (Figure 3G), 245 
indicating the presence of an insulin resistance with impaired glucose tolerance. This data was 246 
consistent with the lack of significant changes in β-cell mass and density (Figure 3H; Supplementary 247 
Figure 1). TRAIL treatment significantly reduced both impaired glucose tolerance and insulin 248 
resistance (Figure 3A-G).  249 
TRAIL treatment significantly reduced NAFLD 250 
To understand why TRAIL reduced impaired glucose tolerance, we looked at the tissues regulating 251 
glucose metabolism, focusing on the liver and skeletal muscle (22). At the end of the study, the HFD 252 
regime did not increase the deposition of fat (lipid droplets) in the skeletal muscle, as assessed by Oil-253 
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Red-O staining (data not shown). By contrast, when we looked at the liver, HFD mice developed 254 
significant steatosis (lipid accumulation >10% of tissue area), which was assessed by Oil-Red-O 255 
staining and by TG content quantification (Figure 4 A-C). The accumulation of more than 5-10% of 256 
fat in the liver, without any primary cause such as viral hepatitis, alcoholic disease, or drug-induced 257 
liver injury is what defines histologically non-alcoholic fatty liver disease (NAFLD) (23). In our study, 258 
HFD mice also exhibited a significant increase in liver macrophage infiltration (Figure 4C-D), but no 259 
fibrosis, which should appear after about 50 weeks of HFD (12). TRAIL treatment significantly 260 
reduced liver steatosis as well as inflammation, therefore ameliorating HFD-induced NAFLD.  261 
TRAIL significantly increased PGC-1α expression in the liver 262 
In parallel studies, we quantitated liver mRNA encoding transcription factors and metabolic enzymes 263 
involved in de novo lipogenesis, fatty acid oxidation, glucose metabolism, and mitochondrial function, 264 
as well as pro-oxidative and proinflammatory molecules. In the liver, HFD significantly increased the 265 
gene expression of Fas, Pparγ, and Il-6, while it decreased that of Cpt1α, Pepck, and Pgc-1α, as 266 
compared to CNT mice (Table 1). In HFD mice, TRAIL significantly decreased the gene expression of 267 
Fas and Il-6, while it increased that of Pparγ and Pgc-1α (Table 1; Figure 4E-F). The increase in 268 
Pparγ and Pgc-1α gene expression that followed TRAIL treatment was observed only in the liver 269 
(Supplementary Figure 2A). Given that PGC-1α regulates energy metabolism and could explain part 270 
of our findings, we further evaluated it by immunostaining. In HFD mice, PGC-1α protein expression 271 
increased and changed pattern of distribution as compared to CNT mice, where it was located in the 272 
nuclei. TRAIL further increased PGC-1α protein expression in the liver (Figure 4C and Figure 4G). 273 
In addition, we quantitated liver mRNA encoding for Atg7, which is a protein essential for autophagy, a 274 
process that has been recently implicated in lipid metabolism regulation (24). Interestingly, an increase 275 
in Atg7 was observed in the liver of HFD+TRAIL mice (Table 1; Supplementary Figure 2A) 276 
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TRAIL significantly reduced lipid droplet accumulation in hepatocytes cultured in a high-fat diet 277 
milieu 278 
To determine whether TRAIL had direct effects on hepatocytes, we used an in vitro model of NAFLD 279 
(9), and cultured HepG2 cells with either palmitate or oleate. It must be noted that, although HepG2 280 
cells are derived from liver hepatocellular carcinoma and they express TRAIL receptors 281 
(Supplementary Figure 2B), they are normally resistant to TRAIL-induced apoptosis (25). MTT assay 282 
showed that palmitate significantly impaired HepG2 cell viability, while oleic acid had no effect on it 283 
(Figure 5A). In HepG2 cells cultured with oleic acid, TRAIL treatment promoted cell viability (Figure 284 
5A), which is consistent with earlier observations that TRAIL can also activate survival pathways (26). 285 
Most importantly, in these cells, TRAIL treatment reduced lipid droplet accumulation by 45% (Figure 286 
5B-C). This effect was confirmed in primary hepatocytes, where TRAIL treatment reduced lipid 287 
droplet accumulation by 39% (Figure 5B-C). In addition, in HepG2 cells cultured with oleic acid, 288 
TRAIL upregulated PPARγ, PGC-1α, and ATG7 gene expression (Figure 6A-C), as well as PGC-1α 289 
protein expression (Figure 6D), while it had no effect on specific proinflammatory markers 290 
(Supplementary Figure 2C).  291 
  292 
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Discussion 293 
The first new finding of this study is that TRAIL significantly ameliorated diet-induced metabolic 294 
abnormalities even when it was administered after the development of impaired glucose tolerance. At 295 
the end of the study, HFD mice became obese and insulin resistant, displaying impaired glucose 296 
tolerance as well as an increase in NEFA and CRP levels. By comparison, the group of HFD+TRAIL 297 
mice showed a significant reduction in body weight gain, NEFA and CRP levels, as well as a 298 
significant amelioration of insulin resistance and impaired glucose tolerance.  299 
Looking at the adipose tissue, TRAIL reduced body weight gain, which was associated with a decrease 300 
in fat weight, adipocyte size, and pgWAT macrophage infiltration. These findings are consistent with 301 
the earlier observations that TRAIL had significant effects on body weight. As a matter of fact, genetic 302 
TRAIL deficiency was found to be associated with increased body weight (8), and we reported that 303 
TRAIL treatment significantly reduced the adiposity of HFD-fed mice as assessed by EchoMRI (7). 304 
More recently, it has been shown that TRAIL has the ability to inhibit adipogenic differentiation 305 
through caspase activation (27). When interpreting our results in light of this finding, it is also by 306 
reducing fat mass that TRAIL could have ameliorated insulin resistance, impaired glucose tolerance, as 307 
well as circulating NEFA and CRP in HFD mice. Excess fat mass has been associated not only with 308 
insulin resistance (20), but also with high levels of NEFA (20) and a low-grade systemic inflammatory 309 
state (21). Moreover, experimental studies have shown that insulin sensitivity and systemic 310 
inflammation improve following adipose tissue removal (28). 311 
In this study, HFD mice developed also hepatic steatosis and inflammation, corresponding to human 312 
non-alcoholic fatty liver disease (NAFLD). At present, NAFLD is found to be a frequent comorbid 313 
factor in the setting of type 2 diabetes (29, 30). It is estimated that about 70% of obese patients with 314 
diabetes have NAFLD and as many as 30-40% have non-alcoholic steatohepatitis (NASH), which is 315 
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characterized by hepatic steatosis with inflammation and/or necrosis (30). Both NAFLD and NASH are 316 
conditions leading to hepatic cirrhosis, end-stage liver disease, and hepatocellular carcinoma (29). 317 
Given that NAFLD is reaching epidemic proportions in diabetic patients (29, 30), it is predicted that 318 
cirrhosis related to NASH will surpass HCV-related cirrhosis as the most common indication for liver 319 
transplantation in the United States (31).  320 
Therefore, the second important finding of this study is that TRAIL treatment markedly reduced 321 
NAFLD in the HFD-fed mouse, where it decreased liver fat content by 47%. Given that NAFLD 322 
generally promotes metabolic abnormalities (29, 30), it is also by reducing liver fat content that TRAIL 323 
might have ameliorated insulin resistance and subclinical inflammation in HFD-fed mice. To date, only 324 
a few studies have addressed the relationship between TRAIL and NAFLD (9, 32). By comparison, this 325 
is the first study describing the direct effect of TRAIL in an experimental model of NAFLD. 326 
Nevertheless, our data is consistent with the finding that TRAIL deficiency worsens NAFLD (9).  327 
There seem to be several mechanisms underlying TRAIL actions on the liver. First, the reduction in 328 
body weight gain, fat mass, and circulating NEFA, which were induced by TRAIL, could have 329 
ameliorated NAFLD in the HFD+TRAIL group. It has been argued that excess storage of hepatic 330 
triglycerides comes mostly from an excess of circulating NEFA (33), which  is usually associated with 331 
visceral obesity (34) or adipose tissue insulin resistance/inflammation (34, 35). Second, the significant 332 
reduction of insulin, which was observed in the HFD+TRAIL group, could have also contributed to 333 
NAFLD amelioration. Hyperinsulinemia usually contributes to liver steatosis. Insulin promotes the 334 
synthesis and inhibits the degradation of lipids (36). It stimulates key lipogenic genes in the liver, such 335 
as fatty acid synthase (FAS), while reducing CPT1, which is the transporter of NEFA into 336 
mitochondria, thereby reducing fatty acid oxidation (36). FAS inhibitors have proven useful to reduce 337 
liver triglyceride content (37). In this study, HFD mice displayed an upregulation of Fas and a 338 
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downregulation of Cpt1a in the liver. TRAIL significantly reduced HFD-induced Fas upregulation, 339 
consistent with the reduction of insulin and liver steatosis. Third, this study clearly shows that TRAIL 340 
also has direct actions on hepatocytes, where it significantly decreased fat content.  341 
In this study, TRAIL significantly reduced lipid droplet accumulation in both HepG2 cells and primary 342 
hepatocytes cultured with oleate. Our results are consistent with the observation that TRAIL treatment 343 
reduces palmitate-induced lipid uptake by 30% in hepatocytes (9). Interestingly, in this study, TRAIL 344 
promoted hepatocyte cell viability and did not have anti-inflammatory effects in vitro, suggesting that 345 
the in vivo reduction of liver inflammation might be secondary to the amelioration of steatosis. In 346 
addition, TRAIL showed a direct stimulatory effect on liver Pparγ and PGC-1α expression in vivo, 347 
which was confirmed in vitro, where TRAIL significantly increased PPARγ and PGC-1α expression in 348 
HepG2 cells. PPARγ is a nuclear receptor expressed in adipose tissue, muscle, and liver. Several 349 
studies have shown that PPARγ agonists significantly reduce hepatic triglyceride content and NAFLD 350 
in patients with diabetes (38, 39). There is a functional interaction between PPARγ and PGC-1α, which 351 
might explain the parallel increase of their gene expression induced by TRAIL (40, 41). PGC-1α, 352 
which is a transcriptional coactivator of nuclear receptors, is currently considered as a key component 353 
of regulatory networks that control cellular actions to adapt to higher cellular demands, such as 354 
mitochondrial function, gluconeogenesis and glucose transport, glycogenolysis, and fatty acid 355 
oxidation (42). Interestingly, PGC-1α polymorphisms have been associated with obesity and increased 356 
risk of diabetes (43, 44). Moreover, both PGC-1α (45) and PGC-1α-responsive genes are coordinately 357 
downregulated in human diabetes (46). When looking at the liver, it has been shown that PGC-1α-358 
deficient mice (47) and liver-specific PGC-1α heterozygous mice (48) develop hepatic steatosis. 359 
Moreover, PGC-1α seems to have a suppressive effect on liver inflammation (49). Therefore, our 360 
results suggest that TRAIL effects on the liver and glucose metabolism might involve PPARγ and/or 361 
PGC-1α actions.  362 
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In addition, based on our in vitro studies, where TRAIL increased ATG7, a possible unifying 363 
hypothesis explaining TRAIL effects on liver steatosis and PGC-1α is that they might be due to 364 
TRAIL-induced liver autophagy (50). Autophagy is a mechanism by which TG content, lipid droplet 365 
number and size is regulated. In this process, lipids are sequestered in autophagosomes where they are 366 
degraded (24). This should stimulate mitochondrial β-oxidation (24). Moreover, autophagy seems to 367 
regulate the flux of cholesterol out of the cell to APOA-I (51), which is the major component of HDL 368 
and could explain the increase in HDL cholesterol that we found in HFD+TRAIL mice. Further studies 369 
are needed to evaluate the mechanisms underlying TRAIL effect on liver steatosis and PGC-1α, as well 370 
as to test in detail the hypothesis that they might include TRAIL actions on liver autophagy.  371 
In conclusion, this study shows that TRAIL was effective in reducing HFD-induced metabolic 372 
abnormalities even when it was administered after the development of impaired glucose tolerance. 373 
Second, this study shows that TRAIL markedly improved NAFLD in HFD-fed mice, and that this was 374 
associated with a significant increase in PGC-1α. Overall, our results shed light on the therapeutic 375 
potential of TRAIL against diabetes, NAFLD, and NASH.      376 
  377 
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Perspective 378 
? Experimental evidence suggests that a circulating protein called TRAIL protects against type 2 379 
diabetes. This study was designed to evaluate whether TRAIL had the potential not only to 380 
prevent, but also to treat diet-induced type 2 diabetes.  381 
? Our in vivo results show that TRAIL had the ability to attenuate the metabolic abnormalities 382 
induced by a high-fat diet, also when TRAIL was given after disease onset (after 4 weeks of 383 
high-fat diet). In particular, TRAIL treatment significantly reduced body weight, impaired 384 
glucose tolerance, and liver steatosis, all of which are frequently associated with type 2 385 
diabetes.  386 
? Our in vitro results show that TRAIL has direct effects on hepatocytes, where it reduces lipid 387 
droplet accumulation. This data sheds light on TRAIL therapeutic potential against impaired 388 
glucose tolerance and NAFLD.  389 
  390 
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Tables 534 
Table 1. Liver gene expression analysis 535 
 CNT HFD HFD + TRAIL HFD vs CNT HFD + TRAIL 
vs CNT 
HFD vs HFD 
+ TRAIL 
De novo lipogenesis 
Fas 1.00 ± 0.10 1.60 ± 0.11 1.20 ± 0.07 <0.01 NS <0.05 
Srebp1a 1.00 ± 0.04 1.17 ± 0.10 1.16 ± 0.11 NS NS NS 
Srebp1c 1.00 ± 0.20 0.70 ± 0.06 1.17 ± 0.21 NS NS NS 
Fatty acid oxidation 
Aox 1.00 ± 0.08 0.77 ± 0.06 0.83 ± 0.07 NS NS NS 
Cpt1a 1.00 ± 0.06 0.51 ± 0.07 0.55 ± 0.07 <0.0001 <0.0001 NS 
Pparα 1.00 ± 0.11 0.75 ± 0.14 0.85 ± 0.15 NS NS NS 
Gluconeogenesis, insulin signaling, insulin sensitivity 
Irs2 1.00 ± 0.09 0.79 ± 0.08 0.74 ± 0.12 NS NS NS 
Pepck 1.00 ± 0.10 0.30 ± 0.09 0.32 ± 0.06 <0.0001 <0.0001 NS 
Pparγ 1.00 ± 0.10 1.82 ± 0.21 2.57 ± 0.20 <0.01 <0.0001 <0.05 
Hnf4 1.00 ± 0.11 0.99 ± 0.11 1.07 ± 0.09 NS NS NS 
Mitochondrial function 
Cit synt 1.00 ± 0.09 1.00 ± 0.11 1.12 ± 0.08 NS NS NS 
Pgc-1α 1.00 ± 0.05 0.41 ± 0.05 0.65 ± 0.03 <0.0001 <0.0001 <0.01 
Pln5 1.00 ± 0.21 0.72 ± 0.07 0.81 ± 0.08 NS NS NS 
Ucp2 1.00 ± 0.11 0.69 ± 0.07 0.79 ± 0.11 NS NS NS 
Sirt-1 1.00 ± 0.07 1.06 ± 0.10 1.03 ± 0.06 NS NS NS 
Oxidative stress and inflammation 
Gp91phox 1.00 ± 0.13 0.83 ± 0.15 0.86 ± 0.16 NS NS NS 
Il-6 1.00 ± 0.18 1.74 ± 0.14 1.16 ± 0.10 <0.01 NS <0.05 
Mcp1 1.00 ± 0.20 1.95 ± 0.25 1.99 ± 0.38 NS NS NS 
Tnfα 1.00 ± 0.14 0.82 ± 0.12 1.14 ± 0.23 NS NS NS 
Autophagy 
Atg7 1.00 ± 0.06 1.33 ± 0.12 1.53 ± 0.11 <0.05 <0.01 NS 
 536 
Fatty acid synthase (Fas), sterol regulatory element binding protein-1a (Srebp1a), and sterol regulatory 537 
element binding protein-1c (Srebp1c) are transcription factors and enzymes involved in lipogenesis. 538 
Acyl-CoA oxidase (Aox), carnitine palmitoyl transferase-1a (Cpt1a), and peroxisome proliferator-539 
activated receptorα (Pparα) are transcription factors and enzymes involved in fatty acid oxidation. Irs2 540 
regulates insulin signaling; Pepck regulates gluconeogenesis; peroxisome proliferator-activated 541 
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receptorγ (Pparγ) sensitizes to insulin. Hepatocyte nuclear factor 4 (Hnf4) is a transcriptional regulator 542 
of gluconeogenic genes. Citrate synthase (Cit synt), which is the pace-making enzyme of Krebs cycle, 543 
and uncoupling protein2 (Ucp2) are localized in mitochondria, while PPARγ coactivator 1α (Pgc-1α), 544 
perilipin 5 (Pln5), and sirtuin-1 (Sirt-1) regulate mitochondrial functions. Gp91phox is a subunit of 545 
NADPH oxidase, which is involved in oxidative stress, interleukin-6 (Il-6), monocyte chemoattractant 546 
protein-1 (Mcp1), and Tnfα are proiflammatory mediators.  Autophagy-related protein 7 (Atg7) is a 547 
molecule involved in autophagy.  548 
  549 
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Figure legends 550 
Figure 1. Treatment protocol. (A) Schematic illustration of the protocol: C57BL/6J mice were fed 551 
either a standard diet (SD; 12% fat) or a high-fat diet (HFD; 60% fat) for 12 weeks. Mice on HFD were 552 
treated either with saline (NaCl 0.9%) or TRAIL weekly between week 5 and week 12. Mice on SD 553 
were treated with saline. (*) Tolerance tests before drug randomization; (**) Tolerance tests at the end 554 
of the study (B) Glucose and insulin tolerance tests performed before drug randomization. Upper 555 
figures show blood glucose and its area under the curve (AUC) during an IPGTT, middle figures show 556 
serum insulin and its AUC during an IPGTT, lower figures show blood glucose and its AUC during an 557 
IPITT (C) Representative images of Cy5.5-TRAIL clearance from the peritoneal cavity, as assessed by 558 
acquisition of fluorescence emission from the peritoneum after an IP injection of 10 μg of Cy5.5-559 
TRAIL. Cy5.5-TRAIL is TRAIL that was labeled with N-hydrosuccinimmide ester of the cyanine 5.5. 560 
Fluorescence emission was collected at 700 nm. For further details, see (14). (D) Circulating human 561 
TRAIL after IP injection of 10 μg of TRAIL. 562 
Figure 2. Body weight, adipose tissue, and inflammation. (A) Body weight throughout the study. 563 
The gray area corresponds to the treatment period. (B) Perigonadal white adipose tissue (pgWAT) 564 
weight at the end of the study. (C-D) Frequency distribution and adipocyte area. (E) Representative 565 
images of pgWAT H&E staining (upper panel; 12.5x, scale bar 50 μm) and F4/80+ macrophages 566 
(lower panels; 25x, scale bar 50 μm). (G) NEFA levels at the end of the study. (H) Total cholesterol 567 
(TC), HDL cholesterol (HDL-C), and triglycerides (TG) at the end of the study. (I) C-reactive protein 568 
levels at the end of the study. Results are presented as mean ± SEM; * p<0.05 vs CNT; # p<0.05 vs 569 
HFD. 570 
Figure 3. Glucose metabolism. (A-F) Glucose and insulin tolerance tests performed at the end of the 571 
study. (A) Blood glucose during an IPGTT; (B) Serum insulin during an IPGTT; (C) Blood glucose 572 
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during an IPITT; (D) Area under the curve (AUC) of the glucose levels during the IPGTT; (E) AUC of 573 
the insulin levles during the IPGTT; (F) AUC of the glucose levels during the IPITT; (G) Fasting 574 
glucose and insulin ant the end of the study. (H) Representative images of pancreatic sections 575 
immunostained for insulin (25x, scale bar 50 μm). Results are presented as mean ± SEM; * p<0.05 vs 576 
CNT; # p<0.05 vs HFD. 577 
Figure 4. Liver changes. (A) Liver triglyceride content; (B) Percentage of hepatic area positive for fat 578 
(stained red) with Oli-Red-O (ORO). (C) Representative images of liver ORO staining (25x, scale bar 579 
50 μm), Picrosirius Red (Sirius Red) staining (12.5X, scale bar 100 μm), CD68+ macrophages (12.5X, 580 
scale bar 100 μm), and PGC-1α staining (12.5X, scale bar 100 μm). (D) Quantification of CD68+ cells 581 
(brown nuclei)/frame liver tissue. (E) Liver mRNA expression of Il-6. Il-6 is for interleukin-6. mRNA 582 
expression is reported as fold induction standardized to the mRNA expression in CNT mice. (F) Liver 583 
mRNA expression of Pgc-1α. Pgc-1α is for peroxisome proliferator-activated receptor-γ coactivator-1 584 
alpha. mRNA expression is reported as fold induction standardized to the mRNA expression in CNT 585 
mice. (G) Quantification of PGC-1α + staining (brown)/area of liver tissue. Results are presented as 586 
mean ± SEM; * p<0.05 vs CNT; # p<0.05 vs HFD. 587 
Figure 5. Hepatic lipid droplet accumulation in vitro. (A) HepG2 cell viability after exposure to 588 
palmitic acid or oleic acid in presence or absence of TRAIL. (B) HepG2 and mPH percentage of cell 589 
surface positive for lipid droplets (dark red staining) with Oil-Red-O (ORO). Cells were incubated with 590 
oleic acid (250 μM) in presence or absence of TRAIL (1 ng/mL). HepG2 is for HepG2 cells and mPH 591 
is for mouse primary hepatocytes. (C) Representative images of HepG2 cells (upper panel) and mouse 592 
primary hepatocytes (lower panel) stained with ORO (20x, scale bar 100 μm). Results are presented as 593 
mean ± SEM; * p<0.05 vs control; # p<0.05 vs oleic acid without TRAIL.  594 
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Figure 6. In vitro studies on HepG2 cells. (A) HepG2 cell mRNA expression of PPARγ; (B) PGC-1α; 595 
(C) ATG7. (D) Representative images of PGC-1α immunostaining on HepG2 cells. Results are 596 
presented as mean ± SEM; * p<0.05 vs control without TRAIL. 597 






Supplementary Materials and Methods
Recombinant human TRAIL (rhTRAIL) preparation
Recombinant soluble human TRAIL (His6-tagged TRAIL) was produced in bacteria as described 
by MacFarlane (1997) and purified by affinity chromatography on Ni2+ affinity resin (Qiagen, 
Hilden, Germany). Determination of total protein concentration in the fractions collected after 
dialysis was performed using a bicinchoninic protein assay with bovine serum albumin as the 
standard, accordingly to the manufacturer’s instructions (Thermo Fisher Scientific Inc., Rockford, 
USA). TRAIL concentration was then quantified by ELISA (R&D Systems, Minneapolis, Minn., 
USA; sensitivity: 2.9 pg/ml; intra- and interassay CV were 3.9 and 6%, respectively) in duplicate 
samples. Selected samples were run in each ELISA plate as internal controls to confirm the 
reproducibility of the determinations over time. The functional activity of each TRAIL preparation 
was tested on the TRAIL-sensitive HL60 cell line by evaluating cell viability and apoptosis after 
treatment of the cells with serial dilutions of each preparation. Finally, purified TRAIL batches 
were tested for the absence of endotoxin by using the ToxinSensor chromogenic LAL endotoxin 
assay kit (GenScript, Piscataway, NJ) and stored at -80°C in single use aliquots.
Labeling of rhTRAIL
Purified rhTRAIL was labeled with N-hydroxisuccinimide ester of the cyanine 5.5 (Amersham 
Biosciences; FluorolinkCy5.5 Monofunctional Dye 5-pack) to form TRAIL-Cy5.5. A freshly 
prepared solution of dye (0.05 mg/mL) in 0.1M sodium carbonate buffer pH 8 was added to 
rhTRAIL (1 mg/mL) in phosphate buffer (vol/vol 1:1). The reagents were incubated by gently 
shaking for 1 hour at room temperature. Excess unconjugated dye was removed by overnight 
dialysis against phosphate buffer pH 7.4. 
Triglyceride measurement with the Beckman Coulter AU5800 analyzer
The procedure for the determination of triglyceride concentration with the Beckman Coulter 
AU5800 analyzer is based on a series of coupled enzymatic reactions. The triglyceride in the 
sample are hydrolyzed by a combinantion of microbial lipases to give glycerol and fatty acids. The 
glycerol is phosphorylated by ATP in the presence of glycerol kinase to produce glycerol-3-
phosphate. The glycerol-3-phosphate is oxidized by molecular oxygen in the presence of glycerol 
phosphate oxidase to produce hydrogen peroxide  (H2O2) and dihydroxyacetone phosphate. The 
formed H2O2 reacts with 4-aminophenazone and N,N-bis(4-sulfobutyl)-3,5-dimethylaniline, 
disodium salt (MADB) in the presence of peroxidase (POD) to produce a chromophore, which is 
red at 660/880 nm. The increase in absorbance at 660/800 nm is proportional to the triglyceride 
content of the sample. 
Supplementary Table 1. Sequences of probes/primer pairs
Gene Primer pair 
Mouse  
Rps9 (F) 5’-GACCAGGAGCTAAAGTTGATTGGA-3’ 
(R) 5’-TCTTGGCCAGGGTAAACTTGA-3’ 
Fas (F) 5’-TCGTGATGAACGTGTACCGG-3’ 
(R) 5’- GGGTGAGGACGTTTACAAAG-3’ 
Srebp1a (F) 5’-ATGGACGAGCTGGCCTTCG-3’ 
(R) 5’- TGTTGATGAGCTGGAGCATGTCTTC-3’ 
Srebp1c (F) 5’-ATGGATTGCACATTTGAAGACATGCT-3’ 
(R) 5’- CCTGTGTCCCCTGTCTCAC-3’ 
Aox (F) 5’-TCACGTTTACCCCGGC-3’ 
(R) 5’- CAAGTACGACACCATACCAC-3’ 
Cpt1a (F) 5’-CCAAGTATCTGGCAGTCGA-3’ 
(R) 5’-CGCCACAGGACACATAGT-3’ 
Ppar? (F) 5'-TCAAGGTGTGGCCCAAGGTTA-3' 
(R) 5'-CGAATGTTCTCAGAAGCCAGCTC-3' 
Irs2 (F) 5’-GACTTCCTGTCCCATCACTTG-3’ 
(R) 5’-TTTCAACATGGCGGCGA-3’ 
Pepck (F) 5’-CCATCCCAACTCGAGATTCTG-3’ 
(R) 5’- CTGAGGGCTTCATAGACAAGG-3’ 
Ppar? (F) 5'-TGTCGGTTTCAGAAGTGCCTTG-3' 
(R) 5'-TTCAGCTGGTCGATATCACTGGAG-3' 
Hnf4 (F) 5’-CAAGAGGTCCATGGTGTTTAAGG-3’ 
(R) 5’-CGGCTCATCTCCGCTAGCT-3’ 
Cit Synt (F) 5’-CAAGCAGCAACATGGGAAGA-3’ 
(R) 5’-GTCAGGATCAAGAACCGAAGTCT-3’ 
Pgc-1? (F) 5’-TGATGTGAATGACTTGGATACAGACA-3’ 
(R) 5’- GCTCATTGTTGTACTGGTTGGATATG-3’ 
Ucp2 (F) 5’-GCCTCTGGAAAGGGAGTTCTC-3’ 
(R) 5’- ACCAGCTCAGCACAGTTGACA-3’ 
gp91phox (F) 5'-TTGGGTCAGCACTGGCTCTG-3' 
(R) 5'-TGGCGGTGTGCAGTGCTATC-3' 
Il-6 (F) 5’-ACCAGAGGAAATTTTCAATAGGC-3’ 
(R) 5’- TGATGCACTTGCAGAAAACA-3’ 
?nf? (F) 5'-AAGCCTGTAGCCCACGTCGTA-3' 
(R) 5'-GGCACCACTAGTTGGTTGTCTTTG-3' 
Atg7 (F) 5'-TGCCTATGATGATCTGTGTC-3' 
(R) 5'-CACCAACTGTTATCTTTGTCC-3' 
Pln5 (F) 5’-TCTCGCCTATGAACACTCTTTG-3’ 
(R) 5’-GGGATGGAAAGTAGGGCTAG-3’ 
Sirt-1 (F) 5’-TGTGAAGTTACTGCAGGAGTG-3’ 
(R) 5’-CAAGGCGAGCATAGATACCG-3’ 
Human  
RPL27 (R) 5’-TGTCCTGGCTGGACGCTACT-3’ 
(F) 5’-CTGAGGTGCCATCATCAATGTT-3’ 
DR4 (F) 5'-CACAAGACCTTCAAGTTTGTCG-3' 
(R) 5'-TGGACACAACTCTCCCAAAG-3' 
DR5 (F) 5'-ATCGTGAGTATCTTGCAGCC-3' 
(R) 5'-TGAGACCTTTCAGCTTCTGC-3' 
DcR1 (F) 5’-GATTACACCAACGCTTCCAAC-3’ 
(R) 5’-TGCCTTCTTTACACTGACACAC-3’ 
DcR2 (F) 5’-GTGGTTGTGGTTGGCTTTTC-3’ 
(R) 5’-CAGGAACTCGTGAAGGACATG-3’ 
PPAR? (F) 5'-AAGGCGAGGGCGATCTTG-3' 
(R) 5'-CCCATCATTAAGGAATTCATGTCA-3' 
PGC-1? (F) 5'-AAACAGCAGCAGAGACAAATGC-3' 
(R) 5'-TTGGTTTGGCTTGTAAGTGTTGTG-3' 
ATG7 (F) 5’-TCGAAAGCCATGATGTCGTCTT-3’ 
(R) 5’-CCAAAGCAGCATTGATGACCA-3’ 
CXCL8 (F) 5’-TTCCTGATTTCTGCAGCTCT-3’ 
(R) 5’-TGTCTTTATGCACTGACATC-3’ 
T?F? (F) 5’-CAGGGACCTCTCTCTAATCA-3’ 
(R) 5’-GGCTACAGGCTTGTCACTCG-3’ 
Gene Probe/Primer pair 
Mouse  
Mcp1 (P) FAM-5’-TCCCTGTCATGCTTCTGGGCCTGT-3’-TAMRA 
(F) 5’-CTTCCTCCACCACCATGCA-3’ 
(R) 5’-CCAGCCGGCAACTGTGA-3’ 
 
  
Supplementary Figure Legends
Supplementary Figure 1. Pancreatic beta cell density and mass. (A) Pancreatic beta cell density 
as assessed by percentage of islet area positive for insulin (brown staining); (B) Pancreatic beta cell 
mass was estimated by multiplying the mean density of staining for insulin in the islet section by 
the mean islet area per area of pancreas. This was adjusted for the pancreatic wet weight for 
individual animals and expressed as fold changes relative to CNT mice.
Supplementary Figure 2. Gene expression in in vivo and in vitro studies. (A) Liver, white 
adipose tissue (WAT), and skeletal muscle mRNA expression of Ppar?? Pgc-??, and Atg7. PPAR??is 
for peroxisome proliferator-activated receptor-???PGC-1?? is for peroxisome proliferator-activated 
receptor-?? coactivator-1 alpha; ATG7 is for autophagy-related protein 7. mRNA expression is 
reported as fold induction standardized to the mRNA expression in CNT mice. Results are 
presented as mean ± SEM; * p<0.05 vs CNT; # p<0.05 vs HFD. (B-C) HepG2 cell mRNA 
expression of TRAIL receptors (DR4, DR5, DcR1, DcR2) and proinflammatory molecules (CXCL8
and TNF?). DR is for death receptor; DcR is for decoy receptor; CXCL8 is for chemokine (C-X-C
motif) ligand 8. Cells were treated with oleic acid (250μM) in presence or absence of rhTRAIL (1 
ng/mL) for 6 hours. For primer pairs see Supplementary Table 1. 
 


